| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6797380 | Journal of the American Academy of Child & Adolescent Psychiatry | 2014 | 21 Pages |
Abstract
α-2 Agonist monotherapy and, possibly to a lesser extent, co-treatment, are significantly superior to placebo for overall, hyperactivity, and inattentive ADHD symptoms. Efficacy advantages need to be balanced against fatigue, somnolence/sedation, hypotension, bradycardia, and possibly QTc prolongation.
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Tomoya MD, Shimon MD, Christoph U. MD,